Evidence map›Paper›PMID 37297906›Full record

ArticleJournal of clinical medicine2023

Pulmonary Functional Outcomes at 3 Months in Critical COVID-19 Survivors Hospitalized during the First, Second, and Third Pandemic Waves.

Cecile Dusart, Jelle Smet, Audrey Chirumberro, Stephanie André, Alain Roman, Marc Claus, Anne-Violette Bruyneel, Ophelie Menez, Stephane Alard, Nathalie De Vos and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cecile DusartDepartment of Pneumology, CHU Saint-Pierre, 1000 Brussels, Belgium.
Jelle SmetDepartment of Pneumology, CHU Saint-Pierre, 1000 Brussels, Belgium.
Audrey ChirumberroDepartment of Pneumology, CHU Saint-Pierre, 1000 Brussels, Belgium.
Stephanie AndréDepartment of Pneumology, Université Libre de Bruxelles, CHU Saint-Pierre, 1000 Brussels, Belgium.
Alain RomanDepartment of Pneumology, Université Libre de Bruxelles, CHU Saint-Pierre, 1000 Brussels, Belgium.ORCID 0000-0003-0561-1890
Marc ClausDepartment of Pneumology, Université Libre de Bruxelles, CHU Saint-Pierre, 1000 Brussels, Belgium.ORCID 0009-0008-5766-0735
Anne-Violette BruyneelGeneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, 1206 Geneva, Switzerland.ORCID 0000-0003-4764-9336
Ophelie MenezDepartment of Pneumology, Université Libre de Bruxelles, CHU Saint-Pierre, 1000 Brussels, Belgium.
Stephane AlardDepartment of Pneumology, Université Libre de Bruxelles, CHU Saint-Pierre, 1000 Brussels, Belgium.
Nathalie De VosDepartment of Pneumology, Université Libre de Bruxelles, CHU Saint-Pierre, 1000 Brussels, Belgium.
Marie BruyneelDepartment of Pneumology, CHU Saint-Pierre, 1000 Brussels, Belgium.ORCID 0000-0002-7035-1266

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite improved management of patients with COVID-19, we still ignore whether pharmacologic treatments and improved respiratory support have modified outcomes for intensive care unit (ICU) surviving patients of the three first consecutive waves (w) of the pandemic. The aim of this study was to evaluate whether developments in the management of ICU COVID-19 patients have positively impacted respiratory functional outcomes, quality of life (QoL), and chest CT scan patterns in ICU COVID-19 surviving patients at 3 months, according to pandemic waves.

methodsWe prospectively included all patients admitted to the ICU of two university hospitals with acute respiratory distress syndrome (ARDS) related to COVID-19. Data related to hospitalization (disease severity, complications), demographics, and medical history were collected. Patients were assessed 3 months post-ICU discharge using a 6 min walking distance test (6MWT), a pulmonary function test (PFT), a respiratory muscle strength (RMS) test, a chest CT scan, and a Short Form 36 (SF-36) questionnaire.

resultsWe included 84 ARDS COVID-19 surviving patients. Disease severity, complications, demographics, and comorbidities were similar between groups, but there were more women in wave 3 (w3). Length of stay at the hospital was shorter during w3 vs. during wave 1 (w1) (23.4 ± 14.2 days vs. 34.7 ± 20.8 days,

conclusionsWith better understanding and management of COVID-19, there was an improvement in PFT, 6MWT, and RMS in ICU survivors 3 months after ICU discharge, regardless of the pandemic wave during which they were hospitalized. However, immunomodulation and improved best practices for the management of COVID-19 do not appear to be sufficient to prevent significant morbidity in critically ill patients.

Indexed as

ARDSchest CTCOVID-19intensive care unitmortalitypandemicpulmonary function testquality of lifewave

Identifiers

PMID37297906
PMCPMC10253272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.